Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Cervical Dysplasia Clinical Trials

A listing of Cervical Dysplasia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (34) clinical trials

LLETZ Under General Versus Local Anesthesia

The investigators conduct a prospective, randomized trial to assess the benefits of performing large loop excision of the transformatione zone (LLETZ) under local anesthesia and compare it to LLETZ under general anesthesia. The primary endpoint of this study is womens satisfaction.

Phase N/A

Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)

This trial will study the effectiveness of photodynamic therapy with aminolaevulinic acid for the treatment of patients with HPV+ low grade cervical intraepithelial neoplasia (LSIL;CIN1).

Phase

Human Papillomavirus and Cervical Dysplasia in Women With Cystic Fibrosis

Background The main risk factor for cervical cancer is the infection by human papillomavirus (HPV), with several intermediate steps between HPV infection and cervical cancer. Cervical screening with pap smear test and HPV vaccination are effective preventions. A high frequency of HPV carriage and of cervical dysplasia have been described ...

Phase N/A

Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia

If you are found to be eligible to take part in this study, you will first have your scheduled VIA and colposcopy. The study doctor will tell you more about this procedure. You will then have proflavine hemisulfate solution (contrast dye) applied to your cervix. Images will be collected with ...

Phase N/A

Community-Driven Cervical Cancer Prevention in Western Kenya

There are many challenges to implementation of cervical cancer prevention in resource-limited countries, despite evidence based screening and treatment strategies. The investigators hypothesize that self-collected HPV specimens offered in a community health campaign setting will

Phase N/A

The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams

Cervical cancer is the second most commonly diagnosed cancer and third leading cause of cancer death in women worldwide. Pre-cancerous cells can be detected with regular Pap smear screening and diagnosed and treated with colposcopy. This process is limited by patient adherence to the follow-up and treatment recommendations. Currently at ...

Phase N/A

Overlooked Population at Risk for AIN.

Anal cancer incidence is increasing and although women compose more than half of all cases and those with HPV related lower genital tract dysplasia/malignancy have an even greater risk screening is currently not recommended. We therefore propose performing a prospective cohort study to determine the prevalence of anal dysplasia in ...

Phase N/A

A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia

2.0 BACKGROUND AND RATIONALE 2.1 Cervical Cancer Etiology and Targets for Intervention Cervical cancer is one of the most common causes of cancer-related deaths in women worldwide. Implementation of widespread screening has created drastic improvements in the incidence of cervical cancer as well as significant decreases in mortality over the ...

Phase

Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)

The primary objectives of this study are as follows: To determine treatment efficacy defined as histologic regression to CIN 1 or less at weeks 20-24 (4 to 8 weeks after the end of imiquimod treatment) in the HPV Vaccine + Imiquimod group compared to control, To determine treatment efficacy defined ...

Phase

Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix

CHAPTER 1: INTRODUCTION 1.1. BACKGROUND Cervical cancer (CC) is the third most common cancer in women, and the seventh overall, with an estimated 530 000 new cases per year. More than 85% of the global burden occurs in low-income countries (LICs). It is responsible for 275 000 deaths per year, ...

Phase